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adaptive immune responses against both viral and tumor anti-
gens. We have shown that therapy with vesicular stomatitis
virus (VSV) engineered to express a tumor-associated antigen
activates antigen-speciﬁc adoptively transferred T cells (adop-
tive cell therapy, ACT) in vivo to generate effective therapy.
The overall goal of this study was to phenotypically characterize
the immune response to VSV+ACT therapy and use the infor-
mation gained to rationally improve combination therapy. We
observed rapid expansion of blood CD8+ effector cells acutely
following VSV therapy with markedly high expression of the
immune checkpoint molecules PD-1 and TIM-3. Using these
data, we tested a treatment schedule incorporating mAb im-
mune checkpoint inhibitors with VSV+ACT treatment. Unlike
clinical scenarios, we delivered therapy at early time points
following tumor establishment and treatment. Our goal was
to potentiate the immune response generated by VSV therapy
to achieve durable control of metastatic disease. Despite the
high frequency of endogenous PD-1+ TIM-3+ CD8+ T cells
following virus administration, antibody blockade did not
improve survival. These ﬁndings provide highly signiﬁcant in-
formation about response kinetics to viroimmunotherapy and
juxtapose the clinical use of checkpoint inhibitors against
chronically dysfunctional T cells and the acute T cell response
to oncolytic viruses.Received 3 October 2016; accepted 26 January 2017;
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Driving the immune system to mount a response against malignancy
has emerged as one of the primary goals of contemporary cancer ther-
apies. In this respect, viroimmunotherapy seeks to harness the immu-
nogenicity of viruses to initiate an anti-tumor response. Led by the
ﬁrst in class viral therapeutic T-VEC, a wealth of preclinical and clin-
ical studies suggest that there is real capacity for these therapies to
translate to clinically meaningful outcomes.1 There is now consider-
able evidence that the ability of oncolytic virotherapy to control local
disease involves both direct viral oncolysis and multiple host-derived
effectors of the innate and adaptive immune system.2,3 Moreover, we,
and others, have focused on understanding how systemically deliv-
ered viral therapies may be used to mount a systemic anti-tumor962 Molecular Therapy Vol. 25 No 4 April 2017 ª 2017response against widely disseminated metastatic disease, a major
challenge to effective cancer therapy.
We have engineered the Rhabdovirus, vesicular stomatitis virus
(VSV) to express tumor-associated antigens (TAAs) to generate a
host immune response against tumors. Previously, we demonstrated
that intra-tumoral administration of VSV controlled B16 melanomas
and generated an immunological recall response to speciﬁc tumor
antigens.4 Additionally, the oncolytic activity of VSV engaged both
adaptive and innate immune responses that contributed signiﬁcantly
to anti-tumor effects, which have been validated in a variety of
models.3 We, and others, have expanded the concept of oncolytic vi-
rotherapy as an immune stimulant against disseminated malignancy
by showing that systemic treatment with VSV expressing a deﬁned tu-
mor associated antigen (such as OVA or gp100) activated adoptively
transferred naive antigen speciﬁc T cells in vivo and led to effective
therapy.5 Taken together, these results demonstrate that oncolytic
viruses can generate signiﬁcant therapy against tumors by various
mechanisms including direct oncolysis, stimulation of anti-tumor
innate immunity, and activation of adaptive T cell responses against
both the virus itself and tumor-associated antigens.6–8
The success of immune inhibitory receptor blocking therapies (im-
mune checkpoint inhibitors) has also highlighted the capacity of
the immune system to contribute to the therapy of even widely
disseminated metastatic disease. These monoclonal antibody thera-
pies block signaling through inhibitory receptors and are thought to
re-invigorate tumor-reactive cells of the immune system that have
become chronically dysfunctional (“exhausted”). These therapies,
most notably those blocking programmed cell death protein-1
(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4),
have demonstrated exciting success in the clinic with roughly 60%
of metastatic melanoma patients responding to combination therapy
www.moleculartherapy.organd 30% of patients achieving a complete response.9 Another
potential therapeutic target is the inhibitory receptor T cell immuno-
globulin and mucin-domain containing-3 (TIM-3) associated with
T cell effector dysfunction in tumor inﬁltrating lymphocytes.10
Expression of both TIM-3 and PD-1 has been strongly linked to
chronic immune dysfunction in both clinical and preclinical
studies.11,12
The immunogenic mechanism of both viroimmunotherapy and
immune checkpoint inhibitors make them ideal candidates for com-
bination therapy. Indeed, there have been several reports of success
utilizing a variety of viral (or other pro-inﬂammatory) therapeutics
in conjunction with immune checkpoint inhibitors.13–15 However,
the therapeutic signiﬁcance of PD-1 and TIM-3 expression is
complex. These receptors are expressed both during acute infection
(as occurs following oncolytic virus administration) and in chronic
dysfunctional states (as occurs in patients with long term exposure
to tumors). The continued expression of inhibitory receptors is asso-
ciated with changes in transcriptional, phenotypic, epigenetic, and
metabolic proﬁles deﬁning a state of chronic dysfunction or exhaus-
tion.16–18 Therefore, the similarities and differences between these
physiological states are likely to have a profound impact on their suit-
ability as targets for enhancing therapy against malignancy at an early
versus late stage.
Here, we used our successful strategy of anti-tumor viroimmunother-
apy combining intravenous VSV-TAA in combination with antigen-
speciﬁc T cells to analyze in detail the immune proﬁles of both endog-
enous and adoptively transferred T cell subsets. Our overall goal was
to predict rationally when, and how, to improve therapy with immune
checkpoint blockade. Despite the presence of a large fraction of
targetable endogenous PD-1+ and TIM-3+ CD8+ T cells following on-
colytic virus administration, antibody blockade of neither molecule
added any signiﬁcant survival beneﬁt. This was in spite of the evi-
dence that inhibitory receptor signaling during TCR activation or
the acute effector differentiation in response to infection leads to
dampening of the immune response.17,19,20 Our ﬁndings are signiﬁ-
cant because they characterize the kinetics of inhibitory receptor
expression following the administration of oncolytic virotherapy
and test a strategy to take advantage of this expression as a therapeutic
target. Furthermore, they highlight the signiﬁcant differences between
inhibitory receptor expression on immune effectors in response to
acute virotherapy administration and the current clinical use of inhib-
itory receptor blockade at late, chronic time points after the develop-
ment of T cell exhaustion.
RESULTS
VSV Viroimmunotherapy and Adoptive Cell Transfer Controls
Metastatic Disease
Building uponourpreviouswork,weutilized a combinationof systemic
VSV-TAA therapy and adoptive cell transfer (ACT) of naive CD8+
transgenic Pmel T cells in a model of metastatic disease.4,5,21 We
generated two models of oligometastatic disease in which C57BL/6
immunocompetent mice were challenged both subcutaneously (s.c.)and intravenously (i.v.) with either B16 or B16-OVA tumors (Fig-
ure 1A).22 In these models, mice eventually developed tumors
throughout the body at late time points when the s.c. tumor was
controlled by therapy. In the less aggressive B16-OVA tumor model,
combination treatment with VSV-hgp100 and adoptive cell transfer
of Pmel T cells signiﬁcantly improved both overall survival (OS) and
median survival (MS) when compared to VSV-hgp100 alone (OS:
p< 0.0001andMS: 22 versus 42days) (Figure 1B).Aswell as prolonging
overall survival, the combination therapy was successful at delaying the
growth of s.c. tumors (Figure 1C). Even at late time points (day 40 or
greater), mice treated with combination therapy were free of gross me-
tastases at the timeof sacriﬁce. In themore aggressiveB16 tumormodel,
as expected, Pmel therapy alone offered no improvement in overall sur-
vival and though VSV-hgp100 + Pmel therapy statistically prolonged
overall survival, it had a modest effect on prolonging median survival
(OS: p < 0.0001 andMS: 15 versus 20 days) (Figures 1D and 1E). These
data extend our previous results by demonstrating that our combina-
tion therapy was successful at treating widely disseminated metastatic
disease.
VSV Immunotherapy Generates an Acute CD8+ Response
Characterized by a High Proportion of Inhibitory Receptor
Expressing Cells
Despite the improvements in overall survival, the combination ther-
apy of VSV-TAA and ACT of Pmel T cells was unable to cure mice
(Figure 1). Therefore, we reasoned that it might be possible to
improve the efﬁcacy of this viroimmunotherapy by understanding
the systemic immune response to treatment. Hence, with the goal
of developing rational strategies to enhance our systemic therapy,
we performed detailed immune phenotyping of mice treated with
VSV through serial sampling of the peripheral blood. Live CD4+ or
CD8+ T cells that had an effector phenotype (CD44hi CD62Llo)
were assessed for their expression of the inhibitory receptors PD-1
and TIM-3 at predetermined time points during the course of therapy
(Figures 2A and 2B). Consistent with a T cell response against an
invading virus, the frequency of CD8+ effector cells peaked rapidly
at 5 days after initial VSV therapy, followed by an immediate contrac-
tion phase (Figure 2C). Amajority of the CD8+ endogenous cells were
double positive for both inhibitory receptors PD-1 and TIM-3, with
80% of all effector CD8+ cells expressing PD-1 and TIM-3 at day
14. The frequency of double positive effector CD8+ T cells returned
to basal levels at a more gradual rate than the contraction of the
overall CD8+ effector cell population (Figure 2D). In contrast, the
frequency of CD4+ effector cells, and their expression of inhibitory re-
ceptors, remained stable (K.G.S. and R.G.V., unpublished data). The
acute expansion and contraction of antigen experienced CD44+ CD8+
splenocytes mirrored the frequency of effector cells expressing both
PD-1 and TIM-3 in the blood (Figures 2E and 2F). We observed
that the increase in the frequency of PD-1+ TIM-3+ cells in the blood
was due primarily to an increase in the fraction of effector cells ex-
pressing TIM-3. At baseline levels, tumor-bearing mice expressed
PD-1 at a high frequency (>60%) of circulating effector cells, whereas
TIM-3 was present on a much smaller fraction of cells (Figures 2G
and 2H). Immediately after administration of VSV immunotherapy,Molecular Therapy Vol. 25 No 4 April 2017 963
Figure 1. VSV-hgp100+ACT Treatment Strategy Controls Disseminated Disease
(A) Mice were challenged first s.c. tumor and i.v. tumor. When the s.c. tumor was visible (day 6–8), CD8+ Pmel T cells were adoptively transferred into the mice. Beginning on
day 7–9, and continuing three times per week, the mice received a total of six doses of VSV-hgp100 or PBS. (B) Mice challenged with s.c. and i.v. B16-OVA received the
treatment schedule above, in addition to a second Pmel treatment on day 21 following tumor challenge. n = 10mice/group. (C) Subcutaneous tumor volumesmeasured three
times weekly with calipers. Each line represents an individual mouse, grouped by treatment. (D) Mice challenged s.c. and i.v. with B16 cells received the treatment schedule
above. n = 11mice/group. (E) Subcutaneous tumor volumesmeasured three times weekly with calipers. Each line represents an individual mouse grouped by treatment. The
significance for overall survival was determined at p < 0.01.
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Figure 2. VSV-hgp100 Therapy Induces Acute CD8+ Effector Cell Expansion and Marked Expression of PD-1 and TIM-3
(A) Mice were challenged first with B16-OVA s.c. tumor then with i.v. tumor. Beginning on day 9, and continuing every other day during the week, the mice received a total of
six doses of VSV-hgp100 or PBS. The mice were sacrificed at the indicated time points. (B) Gating strategy showing representative CD8+ effector (CD44hiCD62Llo) cells and
their expression of PD-1 and TIM-3. (C and D) Blood flow cytometry. The frequencies of effector cells gated on CD8+ cells and frequencies of PD-1+ TIM-3+ cells gated on
CD8+ effectors are shown. Each of the points represents 3–5 mice/group. (E and F) Splenic frequencies of CD8+ CD44+ effector cells and PD-1 and TIM-3 double positive
effector cells. Each of the points represents 1–5 mice/group. (G and H) Frequencies of PD-1 or TIM-3 double negative, single positive, or double positive cells gated on CD8+
effectors in the blood. The above results are representative of three independent experiments with n = 1–5 mice per group. (I and J) Blood tetramer staining for the frequency
and number of CD8+ effector cells reactive to the immunodominant VSVN peptide. (K and L) Splenic staining for the frequency and number of VSVN Tetramer+ CD8+ effector
cells. The median with interquartile range is shown. ****p < 0.0001, ***p < 0.001, **p < 0.01, and *p < 0.05. The significance was determined at p < 0.05.
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Figure 3. VSV Immunotherapy Causes Tumor Infiltration by Inhibitory
Receptor Expressing Effector T Cells
Mice were challenged with B16-OVA and treated with VSV-hgp100 as described in
Figure 2. The tumors were harvested at day 22 post-challenge and analyzed by flow
cytometry. (A) Tumor weight in grams of subcutaneous tumors harvested frommice
at the time of sacrifice. (B and C) The fraction of live cells that were CD8+ or CD4+ in
the tumor. (D and E) The number of CD8+ or CD4+ cells in 50 mg of tumor. (F and G)
The fraction of CD8+ effector cells and the fraction of those effector cells double
positive for expression of the inhibitory receptors PD-1 and TIM-3 (G). The median
and interquartile range are shown. *p < 0.05.
Molecular Therapythe fraction of cells expressing TIM-3 increased dramatically, then
gradually declined to a point where a TIM-3 single positive popula-
tion was actually dominant in the circulation (Figure 2H). The biolog-
ical signiﬁcance of this shift from baseline dominance of PD-1 expres-
sion to TIM-3 expression on circulating effector cells is unknown, but
suggested TIM-3 as a potential target to block. Furthermore, we vali-
dated the speciﬁcity of the above effector T cell population by utilizing966 Molecular Therapy Vol. 25 No 4 April 2017tetramer staining. Data gathered from the blood (Figures 2I and 2J)
and spleen (Figures 2K and 2L) demonstrate that between
20%–40% of CD8+ effector cells recognize the immunodominant
VSV N protein peptide RGYVYQGL. An assessment of tumor
inﬁltrating lymphocyte (TIL) populations was also conducted to
determine the PD-1 and TIM-3 expression status of this population.
Tumors were of similar weights at day 22 post challenge (Figure 3A).
While treatment with VSV-hgp100 showed a trend toward an
increase in the number and fraction of CD8+ and CD4+ cells in the
tumor (Figures 3B–3E), there were no statistically signiﬁcant changes.
Mice treated with VSV-hgp100 did demonstrate a statistically signif-
icant increase in the fraction of CD8+ cells that were of the effector
phenotype (Figure 3F), which expressed both inhibitory receptors
PD-1 and TIM-3 at high levels (Figure 3G).
Targeting PD-1 or TIM-3 Induced by VSV Immunotherapy Does
Not Improve Treatment Outcomes
The sequence of rapid effector cell expansion and contraction seen in
response to VSV immunotherapy (Figure 2) led us to hypothesize that
early inhibitory signaling through PD-1 and TIM-3 may hinder the
capacity of our therapy to drive a more robust anti-tumor response.
Inhibition may occur by causing rapid contraction and inhibitory re-
ceptor-mediated suppression of potentially tumor-reactive effector
cells (either endogenous or adoptively transferred). Alternatively, in-
hibition may occur by dampening the response of VSV reactive host
immune effectors in vivo that contribute to the immunogenic envi-
ronment supporting Pmel activation. Thus, we hypothesized that
early blockade of PD-1 or TIM-3 inhibitory receptor signaling in
combination with VSV immunotherapy would improve treatment
outcomes in tumor-bearing mice by potentiating the immune
response against tumors generated by VSV immunotherapy (Fig-
ure 4A). This differs from clinical studies on the impact of PD-1 or
TIM-3 blockade on late stage, chronically dysfunctional T cells. For
these experiments, we challenged mice with i.v. tumors only to model
widely disseminated metastatic disease. As in our previous tumor
models, the VSV-hgp100+Pmel ACT combination therapy signiﬁ-
cantly improved overall and median survival compared to untreated
mice (OS: p < 0.0001 and MS: 23 versus 53 days) (Figure 4B). The use
of this model also allowed us to extend mouse survival for long-term
study, which was prevented by the rapid growth of the s.c. tumors that
eventually led to the sacriﬁce of all mice in the oligometastatic model
of Figure 1. However, despite a high frequency of PD-1 expressing
CD8+ effectors following virotherapy (Figure 2), the addition of early
PD-1 blocking mAb therapy did not improve overall or median sur-
vival when compared to an isotype antibody control or no antibody
(OS: ISO versus PD-1; p = 0.32 and MS: 56 versus 53 days) (Fig-
ure 4B). To ensure that this was not a function of the hgp100/Pmel
model, we also tested the approach using VSV-OVA and adoptive
transfer of OVA-speciﬁc transgenic OT-I T cells. Similar results
were seen in a less aggressive model of B16-OVA (OS: ISO versus
PD-1; p = 0.55 and MS: 118 days versus not reached) (Figure 4C).
We have previously demonstrated the biological efﬁcacy of the
anti-PD-1 antibody utilized in a model of i.t. Reovirus administration
into B16 tumors.23 Based on the increased frequency of effector cells
Figure 4. Addition of PD-1 or TIM-3 Blocking Antibody to VSV-hgp100+ACT Therapy Does Not Improve Treatment Outcomes
(A) Mice were challenged with i.v. tumor only. The mice were treated with Pmel ACT on day 7 or 8, a second treatment was delivered on day 21. Beginning on day 8 or 9, and
continuing three times per week, the mice received a total of nine doses of VSV-hgp100 or PBS. The mice received six doses of isotype antibody control or immune
checkpoint inhibitor beginning with the third dose of VSV (day 14–17). The antibody was delivered on the same day, after VSV administration. n = 10 mice/group. (B) Mice
were challenged with i.v. B16 tumor and treated with PD-1 inhibitor. (C) Mice were challenged with i.v. B16-OVA tumor and treated with PD-1 inhibitor. (D) Mice were
challenged as in (A), but treated with TIM-3 inhibitor. The significance for overall survival was determined at p < 0.008.
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Molecular Therapyexpressing TIM-3 during the T cell expansion phase of our therapy
(Figure 2), we tested a TIM-3 blocking mAb beginning at the same,
early time point. As with antibody-mediated blockade of PD-1,
anti-TIM-3 therapy had no effect on the overall or median survival
of tumor bearing mice (OS: ISO versus TIM-3; p = 0.51 and MS: 66
versus 54 days) (Figure 4D).
PD-1 Blockade Does Not Alter the Kinetics of Endogenous
Effector T Cells in Response to VSV Therapy
We used a serial phenotyping approach on the mice treated in
Figure 4B to track the kinetics of inhibitory receptor expression on
peripheral blood cells in each individual mouse in response to PD-1
therapy over a broad time window. CD4+ and CD8+ effector cells,
and the frequency of these cells expressing PD-1 and TIM-3, were
gated using the strategy shown in Figure 2. Additionally, endogenous
cells (Thy1.1) were distinguished from adoptively transferred Pmel
T cells (Thy1.1+) (Figure 5A). Mice treated with PD-1 inhibitor
showed very few subsequent phenotypic changes when compared
with untreated or isotype treated mice. The frequency of circulating
CD4+ and CD8+ endogenous effector cells demonstrated similar ki-
netics, irrespective of treatment with isotype control or PD-1 blocking
antibody (Figures 5B and 5C). There was a modest elevation in the
fraction of endogenous CD8+ effector cells between days 24 and 38
in mice treated with PD-1 blockade (Figure 5C), with a small, statis-
tically signiﬁcant increase in the fraction of CD8+ effector T cells in
PD-1 blocking mAb-treated mice compared with no mAb or ISO
treated mice 15 days after VSV therapy. This overall lack of difference
challenged our hypothesis, which postulated that blockade of PD-1
signaling would disrupt the contraction phase of the immune
response generated by VSV. Furthermore, the fraction of CD8+
endogenous effector cells double positive for PD-1 and TIM-3 re-
mained unchanged when either isotype control or PD-1 blocking
mAb was added to the treatment schedule (Figure 5D).
Immune Kinetics of Adoptively Transferred T Cells following
Virotherapy
Interestingly, the fraction, and number, of Thy1.1+ Pmel CD8+ cells
that were adoptively transferred did not undergo the same expansion
as endogenous cells in response to systemic VSV therapy (Figures 5E
and 5F). Furthermore, there were variations in the frequency and
numbers of detected Pmel T cells across all groups over time, with
no distinct expansion/contraction phase or clear response associated
with checkpoint blockade. However, adoptively transferred Pmel
T cells demonstrated a striking shift from naive or non-activated
(CD44lo CD62Lhi) phenotypes to an antigen experienced phenotype,
with nearly 100% of Pmel effectors acquiring the CD44hi CD62Llo
phenotype by 17 days following transfer (Figure 5G). A maximum
of 25%–30% of adoptively transferred cells expressed both inhibitory
receptors PD-1 and TIM-3 at 3 days following transfer and this frac-
tion quickly diminished to5% over a short period of 7 days (Figures
5G and 5H). This was in contrast to 80% of endogenous CD8+
T cells at 9 days following transfer (Figure 5D). Taken together,
Figures 5E–5H demonstrate that there was no signiﬁcant effect
on the immune phenotype of adoptively transferred Pmel T cells968 Molecular Therapy Vol. 25 No 4 April 2017when PD-1 inhibitor was added to the VSV-hgp100+Pmel treatment
strategy. However, the data of Figure 4 emphasize that systemic treat-
ment with oncolytic virus induces different kinetics of expansion and
proﬁles of inhibitory receptor expression on endogenous versus adop-
tively transferred effector T cell populations.
Effects of PD-1 Blockade on Memory T Cell Generation
We also investigated whether PD-1 blockade at an acute time point
after virus administration might impact the nature of the T cell
memory generated when combined with VSV-TAA+ACT therapy.
Using the B16-OVA/VSV-OVA/OT-I model, the peripheral blood
of mice surviving tumor challenge, treated as described in Figure 4C,
was analyzed just prior to, and 1 week after, re-challenge with intra-
venous B16-OVA tumor to model recurrent metastases (Figure 6A).
Figures 6B and 6C demonstrate that re-challenge with tumor did
not induce an increase in the frequency of CD8+ effector cells in cir-
culation. Correspondingly, prior to re-challenge with tumor, there
was no difference in the frequency of CD8+ central memory
(CD44hi CD62Lhi) cells found in circulation when comparing across
all treatment groups. Similarly, the fraction of central memory cells
did not change following tumor re-challenge. To monitor antigen-
speciﬁc immune response, we assessed the fraction of CD8+
T cells in circulation that recognized the SIINFEKL peptide and
their effector phenotype (Figure 6D). We observed that treatment
with PD-1 blocking antibody resulted in no change in the fraction
of cells recognizing this speciﬁc antigen. We also did not observe
a difference in the percent of SIINFEKL tetramer positive cells prior
to, or following, re-challenge with intravenous B16-OVA tumor
(Figures 6E and 6F). Splenocytes evaluated at the day 200 time point
also showed no changes in the frequency of the populations assayed
between treatment groups (K.G.S. and R.G.V., unpublished data).
Overall, there were no statistically signiﬁcant changes in the fre-
quencies of the memory populations evaluated when comparing
treatment groups at each time point.
Pmel T Cells Are Ineffective Unless Adoptively Transferred to a
New Host
Given the lack of a clearly deﬁned VSV-induced expansion of Pmel
T cells (Figure 5), we hypothesized that VSV-gp100+Pmel therapy
of B16 tumors may be limited by the number of effector Pmel cells
which are present following adoptive T cell transfer. To test this hy-
pothesis, we established B16 tumors in Pmel transgenic mice with a
potentially limitless number of Pmel T cells which could act as
anti-tumor effectors after VSV-mediated activation in vivo (Fig-
ure 7A). In a model of the s.c. disease, treatment of Pmel mice with
systemic VSV-hgp100 therapy statistically improved overall survival
with a modest improvement in median survival (OS: p = 0.0005
and MS: 15 versus 24). When the i.v. tumor challenge was added
with the s.c. tumor, no signiﬁcant improvements in overall survival
were observed along with a minimal prolongation of median survival
(OS: 0.062 and MS: 15 versus 19 days) (Figures 7A and 7B). Circu-
lating CD8+ T cells (with the transgenic Va1/Vb13 Pmel receptor)
underwent only a modest differentiation to an effector (CD44hi
CD62Llo) phenotype (Figure 7C), which was in stark contrast to the
Figure 5. Addition of PD-1 or TIM-3 Blocking Antibody Therapy to VSV-hgp100+ACT Therapy Minimally Alters Immune Kinetics
Mice from Figure 3B had serial submandibular vein blood samples taken at the time points indicated in (B)–(H). (A) Gating strategy shows representative plot to distinguish
Pmel adoptively transferred Thy1.1+ from BL/6 endogenous Thy1.1 cells, gated on CD8+ cells. (B and C) Frequencies of effector cells (CD44hiCD62Llo) gated on CD4+
or CD8+ cells. (D) Frequencies of PD-1+ TIM-3+ cells gated on CD8+ effectors. (E and F) Frequency and number of Thy1.1+ Pmel T cells gated on CD8+ cells. (G) Frequency
of effector (CD44hiCD62Llo) cells gated on CD8+ Thy1.1+ cells. (H) Frequencies of PD-1+ TIM-3+ cells gated on CD8+ Thy1.1+ effectors. Each of the points represents
1–5 mice/group. The median with interquartile range is shown. *p < 0.05. The significance was determined at p < 0.05.
www.moleculartherapy.org
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Figure 6. Early Treatment with PD-1 or TIM-3 Blocking Antibody Therapy Does Not Alter Late-Stage Memory Phenotypes
(A) Surviving mice from the experiment in Figure 3C were re-challenged with i.v. B16-OVA on day 193. A submandibular vein bleed was taken 1 day before re-challenge and
the mice were sacrificed 1 week after re-challenge. (B and C) Frequencies of effector (CD44hiCD62Llo) or central memory (CD44hiCD62Lhi) cells gated on CD8+ cells. (D)
Gating strategy to identify SIINFEKL tetramer+ CD8+ cells and effector or central memory phenotypes. (E and F) Frequency of SIINFEKL tetramer+ cells gated on CD8+ cells
and effector cells gated on CD8+ tetramer+ cells. Each of the points represents 3–5 mice/group. The median and interquartile range are shown.
Molecular Therapyrapid and stable differentiation of adoptively transferred Pmel T cells
in BL/6 mice (compare with Figure 5G). The effector cells in VSV
treated Pmel mice expressed inhibitory receptors PD-1 and TIM-3970 Molecular Therapy Vol. 25 No 4 April 2017at roughly the same frequency that adoptively transferred Pmel
T cells had (Figure 7D). Administration of PD-1 therapy in combina-
tion with VSV in a model of the s.c. tumor challenge resulted in no
(legend on next page)
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Molecular Therapysubstantial changes in median or overall survival when compared to
the administration of PD-1 alone (OS: p = 0.055 and MS: 14 versus
21 days) (Figure 7E).
DISCUSSION
Our ﬁrst goal was to conduct kinetic analysis of PD-1 and TIM-3
expression on lymphocytes in the context of oncolytic VSV administra-
tion. Our second goal was to use this information to design a rational
strategy to improve our effective viroimmunotherapy regimen of
VSV-hgp100+Pmel with inhibitory receptor blockade. Our treatment
strategy was ideal for investigating the potential of adding checkpoint
inhibitors because we could easily track the impact of therapy on
both endogenous and exogenous adoptively transferred cell popula-
tions.Weshowhere the immune response following treatmentwithon-
colytic VSV is characterized by an acute expansion of endogenous
CD8+ T cells, followed by contraction, as expected from an anti-viral
immune response (Figure 2). A markedly high proportion of these ex-
panding effector cells expressed both PD-1 and TIM-3.We show at the
peak of acute response to VSV immunotherapy 35% of circulating
and 25% of splenic CD8+ effector cells recognize the immunodomi-
nantVSVNprotein peptide, alongside a proportionwehave previously
demonstrated to have anti-tumor activity.6
This acute proﬁle of inhibitory receptor expression suggested that
either PD-1 and/or TIM-3 might be therapeutic targets to enhance
the efﬁcacy of VSV-hgp100+Pmel in the B16 model. This strategy
was supported by in vitro ﬁndings from others demonstrating that
PD-1 signaling during early TCR activation can disrupt T cell func-
tion and in vivo studies utilizing LCMV, wherein a dysfunctional
phenotype was imprinted on cells during acute effector differentiation
in response to antigen.17,19,20 Studies characterizing the impact of
blocking TIM-3 signaling also provided rationale for this strategy.24,25
In particular, we hypothesized that antibody blockade of PD-1 and
TIM-3 would enhance therapy in three ways: ﬁrst, checkpoint
blockade would directly enhance the activation (de-repression) of
anti-tumor adoptively transferred PD-1+ TIM-3+ Pmel cells; second,
blockade of checkpoint molecules on endogenously activated im-
mune effectors would potentiate their activity directly against tumor;
and ﬁnally, the immune checkpoint blockade may relieve inhibition
of the endogenous anti-viral immune response, which provides a
highly immunogenic environment to support the expansion of both
Pmel and endogenous anti-tumor T cells.
Interestingly, despite the high fraction of endogenous PD-1+ TIM-3+
CD8+ T cells in the blood, spleens, and tumors (Figures 3 and 5D), as
well as a smaller fraction of adoptively transferred PD-1+ TIM-3+Figure 7. Pmel Therapy Is Dependent on the Environment of Adoptive Cell Tra
(A) Pmel transgenic mice were challenged with s.c. B16 tumor and treated with a
were challenged both s.c. and i.v. with B16 tumor cells. The mice were treated as in (A).
The serial submandibular vein bleeds from mice treated in (B) show peripheral blood pop
of PD-1+ TIM-3+ cells gated on CD8+ effector cells (D). Each of the columns represen
mice were treated with three doses of i.v. PD-1 inhibitor beginning with the first dose of V
n = 8 mice/group. The significance for overall survival was determined at p < 0.01.
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antibody blockade of neither molecule added any signiﬁcant survival
beneﬁt (Figure 4). Despite the known inhibitory signaling through
PD-1 and TIM-3 during acute stimulation, the blockade of signaling
through these receptors in our in vivomodel did not signiﬁcantly alter
the kinetics of the immune response observed against systemic VSV
treatment (Figure 5). This includes no difference in the late stage an-
tigen-speciﬁc memory populations found in mice treated with PD-1
compared to those that were not treated or given isotype control anti-
body (Figure 6). Our data do not exclude the possibility that therapy
with VSV-TAA+ACT would be further improved by the combination
of multiple immune checkpoint inhibitors (such as anti-PD-1+TIM-3
or anti-CTLA4+PD-1 etc.). We have not undertaken these experi-
ments here due to the lack of any improvement in therapy afforded
by either anti-PD-1 or anti-TIM-3 therapy alone. These ﬁndings sug-
gest that combination of these two agents may not have dramatic
added efﬁcacy. This is in contrast to the improvement in clinical out-
comes that were observed when patients were treated with single
agent CTLA-4 or PD-1 blocking therapy. In addition, we have also
found that expression of CTLA-4 was not signiﬁcantly upregulated
on CD8+ cell populations or CD4+ FoxP3+ Treg populations by
VSV-hgp100 therapy either with or without added Pmel therapy
(K.G.S. and R.G.V., unpublished data).
Our data also illustrate the importance of understanding the interac-
tions of the host immune system with adoptively transferred T cells in
the context of a strong immunogenic stimulus like VSV. Treatment of
B16 tumors with Pmel ACT alone (in the absence of VSV-hgp100)
was completely ineffective.5 Ongoing studies have shown that this
is due to a rapid loss of adoptively transferred T cells in the absence
of VSV-mediated antigen presentation, suggesting that further com-
bination with checkpoint inhibition is unlikely to have additional
therapeutic effects (K.G.S. and R.G.V., unpublished data). Our results
here show that the immunological environment a T cell is transferred
into shapes its ability to control tumor. Here, we observed that Pmel
T cells in a Pmel mouse were completely ineffective against an estab-
lished tumor even when treated with VSV-hgp100. In contrast, when
a much smaller number of Pmel T cells were adoptively transferred
into BL/6 mice, we observed rapid and stable effector differentiation
of the Pmel T cells with effective anti-tumor therapy (Figures 5G and
7D). Understanding the basis of these effects has signiﬁcant implica-
tions for the development of effective adoptive transfer therapies,
including with chimeric antigen receptor T cells.
We believe that these data are highly signiﬁcant in three principal
ways. First, they re-afﬁrm that not all inhibitory receptor expressionnsfer
total of six doses of VSV-hgp100 or PBS. n = 8 mice/group. (B–D) Pmel mice
n = 10 mice/group. The significance for overall survival was determined at p < 0.05.
ulations of effector (CD44hiCD62Llo) cells gated on CD8+ cells (C) and the frequency
ts 1–5 mice/group. (E) Mice were challenged with B16 tumor cells s.c. only. The
SV (day 9). The antibody was administered on the same day following VSV therapy.
www.moleculartherapy.orgis equal and that the simple presence of inhibitory receptors on im-
mune effector cells following virotherapy is not a guarantee of
improved efﬁcacy through antibody-mediated blockade. Second,
this conclusion highlights the importance of understanding exactly
which immune subsets are relevant to tumor clearance during
different forms of virotherapy. In our model here, therapy is princi-
pally mediated through in vivo activation of adoptively transferred,
naive Pmel T cells. This treatment is enhanced by global immune acti-
vation by the anti-viral immune effector response. Although we
observed the induction of large fractions of inhibitory receptor posi-
tive T cells upon VSV administration (both endogenous and adop-
tively transferred), the induction of PD-1 and TIM-3 expression on
these cells represented markers of acute T cell activation and expan-
sion rather than of chronic T cell dysfunction (exhaustion). In this
context, checkpoint inhibitor blockade might have been ineffective
at enhancing therapy because there was minimal T cell dysfunction
to reverse. Furthermore, these data suggest that an acute immune
response to VSV infection is not suppressed or limited by signaling
through either of the inhibitory receptors expressed on the circulating
or splenic cells assayed. Third, our data illustrate the important differ-
ences between the clinical contexts in which antibody blockade of
checkpoint molecules has been successful and the acute T cell
response to oncolytic viruses, especially in a model such as this where
true T cell exhaustion against tumor antigens has not been induced.
Clinical data demonstrate that targeting checkpoint molecules such as
PD-1 holds considerable promise to re-invigorate exhausted T cell re-
sponses against tumors. However, these data also suggest that check-
point blockade is effective in patients in which an anti-tumor
response exists, but which has become functionally exhausted over
time. In many models of oncolytic virotherapy, including ours here,
checkpoint inhibitor expression on immune effectors is not a reﬂec-
tion of this chronic T cell exhaustion, but rather a marker of acute
T cell expansion. Though it is has been demonstrated that signaling
through both PD-1 and TIM-3 diminish T cell responses by regu-
lating transcription factor activity, it remains to been seen how this
signaling is qualitatively different than the inhibitory signaling that
occurs with T cells possessing a chronically dysfunctional pheno-
type.26,27 We hope these results will stimulate further investigation
into the differences between infection and tumor-induced expression
of inhibitory receptors and serve as a potentially cautionary result for
use of immune checkpoint inhibitors in contexts which may not
reﬂect clinically analogous situations. Therefore, it will be important
to appreciate these differences in future studies of combinations of
oncolytic virotherapy with checkpoint inhibitor blockade. In partic-
ular, it will be informative to develop preclinical models in which
genuine anti-tumor T cell exhaustion is induced before treatments
with oncolytic viruses are attempted in combination with checkpoint
inhibitor blockade.
Importantly, other studies, including from our own laboratory,
have shown successful synergy of checkpoint blockade with oncolytic
virotherapy.13,23,28 These studies indicate that checkpoint inhibitor
expression on various immune effector cells at early time pointscan still be inhibitory to an anti-tumor response under certain cir-
cumstances. For example, we have shown that direct intra-tumoral
Reovirus therapy of B16 tumors can be enhanced by combination
with anti-PD-1 therapy. In that model, therapy was partly mediated
by PD-1 inhibited NK cells that represented a productive target for
inducing a more effective anti-tumor response. In addition, Fourcade
et al. showed that blockade of TIM-3 combined with tumor peptide
vaccination resulted in the expansion of tumor-speciﬁc T cells.29
These studies suggest that perhaps each immunogenic tumor therapy
has a unique activation proﬁle characterized by differential expression
levels of inhibitory receptors on different populations of cells. Under-
standing these variables for each immunotherapy will be critical to
identify if therapy is to be rationally improved. Our data suggest
that the high TIM-3 expression noted on endogenous and exogenous
adoptively transferred cells (Figure 2H) may simply be part of the im-
mune signature of acute VSV infection. Thus, the success of the com-
bination of oncolytic virotherapy with checkpoint inhibitor blockade
will depend upon the virus used, the route of administration, the tu-
mor model, the immune effectors which are responsible for tumor
clearance induced by oncolytic virotherapy, and the amount of im-
mune cell exhaustion which is induced by the tumor model.
In summary, our results here show that combination therapy between
oncolytic virotherapy and checkpoint inhibitor antibody blockade is
not automatically assured of success by the mere presence of check-
point molecules on immune effectors induced by the virus. Instead,
it will be important to monitor inhibitory receptor expression quan-
titatively, kinetically, and (perhaps most signiﬁcantly) qualitatively,
on different immune effector populations following virus administra-
tion. It will also be critical to correlate those data with an understand-
ing of the immunological effector mechanisms by which anti-tumor
therapy is operating in vivo. Finally, better models will need to be
developed which reﬂect the clinical situation in which genuinely ex-
hausted tumor-reactive T cells exist prior to treatment with oncolytic
viruses and checkpoint blockade.
MATERIALS AND METHODS
Cells and Viruses
Murine B16 cells were maintained in DMEMwith 10% (v/v) fetal calf
serum. B16-OVA cells are B16 cells transfected with pcDNA3.1OVA
and were maintained in 10% DMEM with 5 mg/mL G418 selection
media. All cell lines were regularly shown to be free of Mycoplasma
infection. All VSV used was generated as previously described.30
Brieﬂy, VSV (Indiana serotype) expressing tumor-associated antigens
was generated by cloning the respective antigen into the pVSV-XN2
plasmid by inserting between XhoI and NheI restriction sites between
the VSV G and L proteins. All viruses were titered by standard plaque
assay on BHK cells.
In Vivo Studies
Female C57BL/6 mice were obtained from The Jackson Laboratory at
6–8 weeks of age and maintained in a pathogen-free BSL2 biohazard
certiﬁed housing facility. Mice were challenged with tumor cells in a
total volume of 100 mL of PBS either s.c. in the right lower limb or i.v.Molecular Therapy Vol. 25 No 4 April 2017 973
Molecular Therapythrough the tail vein. Mice were challenged with B16-OVA s.c. at
a dose of 1–5  105 cells and i.v. at a dose of 4  104 cells. For
studies with B16, mice were challenged with 2.5  105 cells s.c. and
with 4  104 cells i.v. For i.v. B16 tumor re-challenge, 4  105 cells
were delivered. In studies where mice were challenged with both a
s.c. and i.v. tumor, the s.c. tumor was delivered ﬁrst followed 2 or
3 days later with an i.v. tumor. All mice with the s.c. challenge had
their tumors measured three times weekly with calipers. All mice
with the i.v. tumor were checked for signs of distress (e.g., lethargy
and labored breathing) daily. The presence of a systemic tumor was
monitored at the time of death by conducting a necropsy, taking
note of any gross metastatic disease. There were six or nine doses
of VSV that were administered in 100 mL of PBS, i.v., three times
weekly, at a dose of 5  106 PFU. ACT therapy was the delivery of
1  106 CD8+ cells isolated by a magnetic bead separation kit (Milte-
nyi Biotec) from transgenic OT-1 or Pmel combined spleens and
lymph nodes.31,32 ACT was delivered i.v. through the tail vein in
100 mL of PBS. Monoclonal blocking antibodies were administered
as six doses of 250 mg each in 100 mL of PBS. Anti-PD1 antibody
(RMP1-14) and anti-TIM3 antibody (RMT3-23) were delivered i.p.
three times weekly (BioXCell). Rat IgG isotype control antibodies
were delivered at the same dose and in the same manner (Jackson Im-
munoResearch). All animal studies were conducted in accordance
with the Mayo Clinic Institutional Animal Care and Use Committee
guidelines.
Flow Cytometry
Flow cytometry was performed on freshly explanted spleens, blood, or
tumors. Blood was taken either serially in a 200 mL submandibular
vein bleed or from cardiac puncture at the time of sacriﬁce. Blood was
collected in heparinized tubes, washed twice with ACK lysis buffer,
and re-suspended in PBS for staining. Spleens were crushed through
100 mm ﬁlters and washed with PBS. Following one wash with ACK
lysis buffer, splenocytes were re-suspended in PBS for ﬂow cytometry.
Tumors were weighed then crushed as the spleens were and washed
twice with PBS. The equivalent of 50 mg of tumor, or the entire vol-
ume if 50 mg was not available, was suspended in PBS then analyzed
by ﬂow cytometry. There were 1 to 1.5 million events that were
collected during ﬂow cytometry analysis or until the entire sample
was analyzed. All samples were ﬁxed in 4% formalin and analyzed us-
ing a modiﬁed BD FACSCanto II ﬂow cytometer. Antibody clones
used include: CD8a (53-6.7), CD4 (RM4-5), CD44 (IM7), CD62L
(MEL14), PD1 (RMP1-30), TIM3 (RMT3-23), H-2Kb restricted
OVA peptide SIINFEKL tetramer (MBL International), Thy1.1
(H1551), and Zombie NIR Fixable Viability Dye (BioLegend). The
following reagent was obtained through the NIH Tetramer Core
Facility: H-2Kb restricted VSV N peptide tetramer (RGYVYQGL).
All data were analyzed using FlowJo software (FlowJo). Biexponential
transformation was carried out on ﬁgures showing gating strategies to
improve visualization.
Statistical Analysis
All statistical analysis was conducted using GraphPad Prism software
(GraphPad Software). All survival analysis was conducted using log974 Molecular Therapy Vol. 25 No 4 April 2017rank tests. The threshold for signiﬁcance was determined by using
the Bonferroni correction for multiple comparisons. All quantitative
ﬂow cytometry data depict median values of a treatment group with
error bars showing interquartile range of the sample sizes listed in the
respective ﬁgure legends. To analyze quantitative ﬂow cytometry data,
one-way ANOVA testing was conducted with a Tukey post-test, p
values reported from these analyses were corrected to account for
multiple comparisons. For comparisons between two groups, an un-
paired t test was conducted.
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